Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

(NEXSTAR) – Over 141,000 bottles of cholesterol medication have been recalled due to “failed dissolution specifications,” suggesting that the drugs did not pass a solubility test, or failed to ...

Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain lifestyle changes.

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...

An oral GLP-1 receptor agonist, Rybelsus will be available in 7-mg and 14-mg doses. "As the only FDA-approved GLP-1 therapy in a pill, now recognized for its proven cardiovascular benefits, a new ...